AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33971764 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session psychoeducational program
Number of subjects: 60
Study 33971764 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 60
Study 33032643 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) boost of 18 Gy in 3 fractions
Number of subjects: 26
Study 33032643 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) boost of 21 Gy in 3 fractions
Number of subjects: 26
Study 33032643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ADT, WPRT, and SBRT boosts
Number of subjects: 26
Study 36163947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 34
Study 36163947 — intervention group
Group type: COMPARATOR
Intervention: Ravulizumab
Number of subjects: 34
Study 36163947 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 34
Study 34039435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 497
Study 34039435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor®
Number of subjects: 497
Study 34039435 — intervention group
Group type: COMPARATOR
Intervention: Control (neither SSO nor Aquaphor)
Number of subjects: 497
Study 35776146 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-tumor ADC measurements
Number of subjects: 170
Study 35776146 — intervention group
Group type: COMPARATOR
Intervention: Single-slice ADC measurements
Number of subjects: 170
Study 35776146 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-radiological model
Number of subjects: 170
Study 35776146 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 170
Study 35776146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 170
Study 34298438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg oral)
Number of subjects: 60
Study 34298438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33055122 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) once daily for 30 days
Number of subjects: 24
Study 33055122 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) twice daily for 30 days
Number of subjects: 24
Study 33651731 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training program with random recovery times between sets (n = 10)
Number of subjects: 20
Study 33651731 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study 33539761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (DVR)
Number of subjects: 941
Study 32011721 — intervention group
Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (series of text messages)
Number of subjects: 3719
Study 32011721 — intervention group
Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (response efficacy messages used)
Number of subjects: 3719
Study 32011721 — intervention group
Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (message framing)
Number of subjects: 3719
Study 32011721 — intervention group
Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (overall acceptance)
Number of subjects: 3719
Study 32011721 — intervention group
Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (response rate)
Number of subjects: 3719
Study 32011721 — intervention group
Group type: EXPERIMENTAL
Intervention: Text2Connect intervention (self-efficacy messaging)
Number of subjects: 3719
Study 35073301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation training
Number of subjects: 80
Study 35073301 — intervention group
Group type: COMPARATOR
Intervention: Audiovisual training
Number of subjects: 80
Study 33730454 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 low-dose group (10 mg/kg)
Number of subjects: 4623
Study 33730454 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 high-dose group (30 mg/kg)
Number of subjects: 4623
Study 33730454 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 4623
Study 33730454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled VRC01 groups
Number of subjects: 4623
Study 33730454 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 recipients
Number of subjects: 4623
Study 33730454 — intervention group
Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 4623
Study 616874768 — intervention group
Group type: EXPERIMENTAL
Intervention: Female within the healthy weight range
Number of subjects: 201
Study 616874768 — intervention group
Group type: COMPARATOR
Intervention: Female with obesity
Number of subjects: 201
Study 35112416 — intervention group
Group type: EXPERIMENTAL
Intervention: First wave of COVID-19
Number of subjects: 42253
Study 34043029 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive transpiriformis approach
Number of subjects: 106
Study 34043029 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral approach
Number of subjects: 106
Study 32628117 — intervention group
Group type: EXPERIMENTAL
Intervention: CaringGuidance (unguided web-based psychoeducational distress self-management program)
Number of subjects: 54
Study 35775042 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-target group (SASD bursa and LHBT sheath corticosteroid injection)
Number of subjects: 60
Study 35775042 — intervention group
Group type: COMPARATOR
Intervention: Single-target group (SASD bursa corticosteroid injection alone)
Number of subjects: 60
Study 33184084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 1.4 mg naloxone
Number of subjects: 200
Study 33184084 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular 0.8 mg naloxone
Number of subjects: 200
Study 33357171 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention aimed at preventing aggression in PWD
Number of subjects: 228
Study 33357171 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 228
Study 33211124 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine interventional strategy in addition to optimal medical therapy
Number of subjects: 0
Study 33211124 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 0
Study 33211124 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA) as a diagnostic tool
Number of subjects: 0
Study 35412416 — intervention group
Group type: EXPERIMENTAL
Intervention: Home quarantine
Number of subjects: 57
Study 35412416 — intervention group
Group type: COMPARATOR
Intervention: Control group (people seeking laboratory testing for suspected Sars-CoV-2 infection)
Number of subjects: 57
Study 35262901 — intervention group
Group type: EXPERIMENTAL
Intervention: MSB11022 via Autoinjector (AI)
Number of subjects: 216
Study 35262901 — intervention group
Group type: COMPARATOR
Intervention: MSB11022 via Pre-filled Syringe (PFS)
Number of subjects: 216
Study 33313734 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Health Team (WHT)
Number of subjects: 750
Study 33313734 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Group Education (PC-GE)
Number of subjects: 750
Study 33313734 — intervention group
Group type: COMPARATOR
Intervention: Usual VA Primary Care (UPC)
Number of subjects: 750
Study 35544130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegulicianine fluorescence-guided system (pFGS)
Number of subjects: 234
Study 35544130 — intervention group
Group type: COMPARATOR
Intervention: Standard pathology assessment
Number of subjects: 234
Study 32900583 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (100 billion cfu/day of Lactococcus lactis subsp. Lactis LL358, Lactobaccillus salivarius LS159, Lactobaccillus pentosus LPE588) for 6 months
Number of subjects: 56
Study 32900583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 32900583 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 56
Study 33645398 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 11
Study 33645398 — intervention group
Group type: COMPARATOR
Intervention: Non-synchronized Nasal Intermittent Positive Pressure Ventilation (nsNIPPV)
Number of subjects: 11
Study 32444296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injection (ISWI)
Number of subjects: 150
Study 32444296 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (75 mg intramuscular injection)
Number of subjects: 150
Study 32444296 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.5 cm3 isotonic saline injection)
Number of subjects: 150
Study 32668410 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Training Group (CTG)
Number of subjects: 41
Study 32668410 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training Group (ITG)
Number of subjects: 41
Study 36342854 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct instruction
Number of subjects: 81
Study 36342854 — intervention group
Group type: COMPARATOR
Intervention: Indirect exposure
Number of subjects: 81
Study 34130783 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment based on ICF-CY Core Sets
Number of subjects: 122
Study 34130783 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation mode (Control)
Number of subjects: 122
Study 34130783 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors intervention in observation group
Number of subjects: 122
Study 33361100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500 mg, three times daily for 5 days)
Number of subjects: 392
Study 33361100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 392
Study 33361100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 32979076 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut supplementation (15% of total energy, ≈30–60 g/day)
Number of subjects: 211
Study 32979076 — intervention group
Group type: COMPARATOR
Intervention: Control (abstaining from walnuts)
Number of subjects: 211
Study 35055603 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative video intervention
Number of subjects: 120
Study 35055603 — intervention group
Group type: COMPARATOR
Intervention: Verbal standard information (Control)
Number of subjects: 120
Study 32975164 — intervention group
Group type: EXPERIMENTAL
Intervention: MFS features (graph, expected change trajectory line, alert, treatment suggestions)
Number of subjects: 299
Study 32975164 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphs
Number of subjects: 299
Study 32975164 — intervention group
Group type: EXPERIMENTAL
Intervention: All MFS features
Number of subjects: 299
Study 32556354 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection (Group 1)
Number of subjects: 68
Study 32556354 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (Group 2)
Number of subjects: 68
Study 35656988 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCH-DM score
Number of subjects: 12028
Study 35656988 — intervention group
Group type: EXPERIMENTAL
Intervention: TRS-HFDM score
Number of subjects: 12028
Study 34351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone rescue (oxycodone, 5 mg as second-line therapy)
Number of subjects: 118
Study 34351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen rescue (ibuprofen, 600 mg as second-line therapy)
Number of subjects: 118
Study 34351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone rescue
Number of subjects: 118
Study 34351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen rescue
Number of subjects: 118
Study 34351376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 118
Study 34351376 — intervention group
Group type: COMPARATOR
Intervention: Nonopioid users (acetaminophen only or acetaminophen and ibuprofen)
Number of subjects: 118
Study 33180513 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy
Number of subjects: 65
Study 32060665 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated granules of doravirine, lamivudine, and TDF
Number of subjects: 24
Study 32060665 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated doravirine granules
Number of subjects: 24
Study 32060665 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated and coated doravirine granules with pudding
Number of subjects: 24
Study 32060665 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine granules with apple sauce
Number of subjects: 24
Study 32060665 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine granules with pudding or apple sauce
Number of subjects: 24
Study 32060665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir granules with pudding or apple sauce
Number of subjects: 24
Study 35624408 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant 10 mg
Number of subjects: 47
Study 35624408 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant 50 mg
Number of subjects: 47
Study 35624408 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant 200 mg
Number of subjects: 47
Study 35624408 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant 750 mg
Number of subjects: 47
Study 35624408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 34323019 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated approval pathway
Number of subjects: 125
Study 34323019 — intervention group
Group type: COMPARATOR
Intervention: Regular approval pathway
Number of subjects: 125
Study 34323019 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival endpoints
Number of subjects: 125
Study 34323019 — intervention group
Group type: EXPERIMENTAL
Intervention: WCLFU exceeding FI
Number of subjects: 125
Study 34323019 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of effect
Number of subjects: 125
Study 34323019 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 randomization
Number of subjects: 125
Study 35813621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equations for visceral fat area (VFA) based on age, waist circumference (WC), and neck circumference (NC) for men: VFA=3.7×age+2.4×WC+5.5×NC‐443.6
Number of subjects: 721
Study 35813621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equations for visceral fat area (VFA) based on age, waist circumference (WC), and neck circumference (NC) for women: VFA=2.8×age+1.7×WC+6.5×NC‐367.3
Number of subjects: 721
Study 33419167 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 100
Study 33419167 — intervention group
Group type: COMPARATOR
Intervention: Control group without kinesio taping (NKT)
Number of subjects: 100
Study 34581911 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release capsules (viloxazine ER; Qelbree™) 100-600 mg/day
Number of subjects: 1354
Study 34581911 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release capsules (viloxazine ER; Qelbree™)
Number of subjects: 1354
Study 34581911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1354
Study 33350762 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 55
Study 33350762 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on therapy
Number of subjects: 55
Study 34953433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular resonance breathing (0.1 Hz/6 breaths per minute)
Number of subjects: 57
Study 34953433 — intervention group
Group type: COMPARATOR
Intervention: Sham breathing (∼0.23 Hz/14 breaths per minute)
Number of subjects: 57
Study 32918337 — intervention group
Group type: EXPERIMENTAL
Intervention: Calystegines (specifically calystegine A3) measured in urine after potato consumption
Number of subjects: 0
Study 32918337 — intervention group
Group type: COMPARATOR
Intervention: Controlled food intervention study
Number of subjects: 0
Study 32918337 — intervention group
Group type: COMPARATOR
Intervention: Calystegine biomarkers
Number of subjects: 0
Study 35344784 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg once daily for 180 days
Number of subjects: 312
Study 35344784 — intervention group
Group type: COMPARATOR
Intervention: No rosuvastatin (control)
Number of subjects: 312
Study 32024944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetics dosing
Number of subjects: 263
Study 32024944 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing
Number of subjects: 263
Study 36629127 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational Process Improvement Intervention (OPII)
Number of subjects: 21
Study 36629127 — intervention group
Group type: COMPARATOR
Intervention: Early condition
Number of subjects: 21
Study 36629127 — intervention group
Group type: COMPARATOR
Intervention: Delayed condition
Number of subjects: 21
Study 36629127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of leadership with high staff responsiveness
Number of subjects: 21
Study 33435918 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive ceftriaxone
Number of subjects: 1480
Study 33435918 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CAS ≥50%
Number of subjects: 1480
Study 32757545 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood glucose (SMBG)
Number of subjects: 54
Study 32757545 — intervention group
Group type: COMPARATOR
Intervention: As-usual treatment (Control Group)
Number of subjects: 54
Study 34348355 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line drugs for neuropathic pain
Number of subjects: 107
Study 34348355 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive studies
Number of subjects: 107
Study 34348355 — intervention group
Group type: COMPARATOR
Intervention: Negative studies
Number of subjects: 107
Study 32854094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic rice (80 g) administered orally for 20 weeks
Number of subjects: 0
Study 32854094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic rice (5 g and 20 g) administered orally
Number of subjects: 0
Study 32854094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic rice (80 g) administered orally
Number of subjects: 0
Study 32060552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive distraction (DIS) during meal consumption (n = 55)
Number of subjects: 119
Study 32060552 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) without distraction (n = 64)
Number of subjects: 119
Study 32060552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive distraction (DIS)
Number of subjects: 119
Study 34561057 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum mobile support application
Number of subjects: 124
Study 34561057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no application)
Number of subjects: 124
Study 32493447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg tablet, 2 tablets daily for 1 to 3 months
Number of subjects: 282
Study 32493447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar in form and taste to hydroxychloroquine)
Number of subjects: 282
Study 35766564 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Processed Diet (MPD)
Number of subjects: 60
Study 35766564 — intervention group
Group type: COMPARATOR
Intervention: Chinese Government-Recommended Diet (GRD)
Number of subjects: 60
Study 34793746 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable intragastric balloon (aIGB) with lifestyle intervention
Number of subjects: 288
Study 34793746 — intervention group
Group type: COMPARATOR
Intervention: Control (lifestyle intervention alone)
Number of subjects: 288
Study 35261113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training group (TG)
Number of subjects: 0
Study 35261113 — intervention group
Group type: COMPARATOR
Intervention: Active control group (ACG)
Number of subjects: 0
Study 35261113 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group (NCG)
Number of subjects: 0
Study 33361495 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training with traditional exercise and exergaming, twice a week for 12 weeks
Number of subjects: 31
Study 33361495 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise sessions (active control group)
Number of subjects: 31
Study 36109006 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal inverted ILM flap technique
Number of subjects: 65
Study 36109006 — intervention group
Group type: COMPARATOR
Intervention: Conventional ILM peeling (control)
Number of subjects: 65
Study 36109006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 65
Study 33422659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 61
Study 33422659 — intervention group
Group type: COMPARATOR
Intervention: No pessary
Number of subjects: 61
Study 34450687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral injection technique with a high G prime filler
Number of subjects: 30
Study 34450687 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique with a low G prime filler
Number of subjects: 30
Study 32592578 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill (AGT) combined with conventional rehabilitation (CR)
Number of subjects: 45
Study 32592578 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR)
Number of subjects: 45
Study 35099294 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop control (CLC) insulin delivery
Number of subjects: 16
Study 34322552 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC method
Number of subjects: 1937
Study 34322552 — intervention group
Group type: COMPARATOR
Intervention: 5As method
Number of subjects: 1937
Study 36355674 — intervention group
Group type: EXPERIMENTAL
Intervention: Gift giving (Study 1)
Number of subjects: 574
Study 36355674 — intervention group
Group type: EXPERIMENTAL
Intervention: Written note of appreciation to a close other (Study 2)
Number of subjects: 574
Study 36355674 — intervention group
Group type: COMPARATOR
Intervention: Gift keeping (Study 1)
Number of subjects: 574
Study 36355674 — intervention group
Group type: COMPARATOR
Intervention: Neutral control task (Study 1)
Number of subjects: 574
Study 36355674 — intervention group
Group type: COMPARATOR
Intervention: Written reflection of a time when they received social support (Study 2)
Number of subjects: 574